Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pradere

Showing results (131-140 of 412) with videos related to

Pageof 42
Sort By:
Urologic Oncology|January 11, 2021
Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic reviewEkaterina Laukhtina, Benjamin Pradere, Keiichiro Mori, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|August 28, 2023
A Standardized Method for Estimating the Carbon Footprint of Disposable Minimally Invasive Surgical Devices: Application in Transurethral Prostate SurgeryVincent Misrai, Enrique Rijo, Jean-Baptiste Cottenceau, et al.
World Journal of Urology|August 7, 2023
5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims dataFrancesco Del Giudice, Federico Belladelli, Frank Glover, et al.
European Urology Oncology|March 24, 2021
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisFahad Quhal, Keiichiro Mori, Andreas Bruchbacher, et al.
Immunotherapy|July 6, 2023
Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysisTatsushi Kawada, Takafumi Yanagisawa, Kensuke Bekku, et al.
Cancer Treatment Reviews|June 21, 2021
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysisKeiichiro Mori, Benjamin Pradere, Fahad Quhal, et al.
European Urology Focus|June 13, 2026
First-line Therapy for Metastatic Renal Cell Carcinoma: An Updated Network Meta-analysis using Final Follow-up DataTakafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, et al.
Journal of Endourology|December 21, 2021
Predictive Factors of Early Postoperative Complications After Robot-Assisted Radical Cystectomy for Urothelial Bladder CarcinomaMarie Mermier, Pierre Baron, Mathieu Roumiguié, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 29, 2025
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updatesTakafumi Yanagisawa, Akihiro Matsukawa, Jeremy Yuen-Chun Teoh, et al.
Minerva Urology and Nephrology|April 29, 2025
Radical cystectomy for bladder cancer in solid organ transplant recipientsElena Tonin, Lorenzo Bianchi, Angelo Mottaran, et al.
Pageof 42

Showing results (131-140 of 412) with videos related to

Sort By:
Pageof 42
Urologic Oncology|January 11, 2021
Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic reviewEkaterina Laukhtina, Benjamin Pradere, Keiichiro Mori, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|August 28, 2023
A Standardized Method for Estimating the Carbon Footprint of Disposable Minimally Invasive Surgical Devices: Application in Transurethral Prostate SurgeryVincent Misrai, Enrique Rijo, Jean-Baptiste Cottenceau, et al.
World Journal of Urology|August 7, 2023
5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims dataFrancesco Del Giudice, Federico Belladelli, Frank Glover, et al.
European Urology Oncology|March 24, 2021
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisFahad Quhal, Keiichiro Mori, Andreas Bruchbacher, et al.
Immunotherapy|July 6, 2023
Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysisTatsushi Kawada, Takafumi Yanagisawa, Kensuke Bekku, et al.
Cancer Treatment Reviews|June 21, 2021
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysisKeiichiro Mori, Benjamin Pradere, Fahad Quhal, et al.
European Urology Focus|June 13, 2026
First-line Therapy for Metastatic Renal Cell Carcinoma: An Updated Network Meta-analysis using Final Follow-up DataTakafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, et al.
Journal of Endourology|December 21, 2021
Predictive Factors of Early Postoperative Complications After Robot-Assisted Radical Cystectomy for Urothelial Bladder CarcinomaMarie Mermier, Pierre Baron, Mathieu Roumiguié, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 29, 2025
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updatesTakafumi Yanagisawa, Akihiro Matsukawa, Jeremy Yuen-Chun Teoh, et al.
Minerva Urology and Nephrology|April 29, 2025
Radical cystectomy for bladder cancer in solid organ transplant recipientsElena Tonin, Lorenzo Bianchi, Angelo Mottaran, et al.
Pageof 42